# US 2026/0091000 A1 · Methods and systems for ablation of the renal pelvis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091000 A1
- Document ID: US20260091000A1
- Status: Published application
- Kind: A1
- Application number: 19/051,821
- Filed: 2025-02-12
- Published: 2026-04-02
- Earliest claimed: 2020-11-13
- Assignees: Verve Medical, Inc.
- Applicants: Verve Medical, Inc.
- Inventors: Terrence J. Buelna; Adam Gold; Rahul Rao
- Web page: https://patentgrep.com/patent/US20260091000A1

## CPC

- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61B 18/1492: {having a flexible, catheter-like structure, e.g. for heart ablation (A61B18/1477 takes precedence)}
- A61B 2017/320008: {Scrapers}
- A61B 2017/320069: {for ablating tissue}
- A61B 2018/00214: {Expandable means emitting energy, e.g. by elements carried thereon}
- A61B 2018/0022: {Balloons}
- A61B 2018/00267: {having a basket shaped structure}
- A61B 2018/00434: {Neural system}
- A61B 2018/00511: {Kidney}
- A61B 2018/00577: {Ablation}
- A61B 2018/00797: {measured by multiple temperature sensors}
- A61B 2018/00821: {measured by a thermocouple}
- A61B 2018/044: {the surgical action being effected by a circulating hot fluid}
- A61B 2018/1417: {Ball}
- A61B 2018/1435: {Spiral}
- A61B 2018/1861: {with an instrument inserted into a body lumen or cavity, e.g. a catheter}
- A61N 1/325: {for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body (electrodes for external use A61N1/0428)}
- A61N 7/022: {intracavitary}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

Apparatus, systems, and methods provide access to the renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances to ablate a thin layer of tissue lining at least a portion of the renal pelvis to disrupt renal nerves within the tissue lining of the renal pelvis

## Claims

### Claim 1

(canceled)

### Claim 2

A method for treating hypertension in a patient, the method comprising:
inserting a sheath through a ureter of the patient into a renal pelvis of the patient such that a distal end of the sheath is positioned within the renal pelvis or within a transition region where the ureter expands to meet the renal pelvis;
inserting an effector through the sheath and through the ureter of the patient into the renal pelvis of the patient such that a distal end of the effector is positioned within the renal pelvis or within a transition region where the ureter expands to meet the renal pelvis;
advancing the effector from the sheath into the renal pelvis; and
actuating the effector to contemporaneously create a plurality of discrete lesions in the renal pelvic tissue to disrupt the function of nerves contained in the renal pelvic wall;
wherein the effector is a catheter, an ultrasound transducer, or a deployable needle; and
wherein actuating the effector disrupts or ablates primarily afferent or efferent renal nerves contained in the renal pelvic wall tissue.

### Claim 3 (depends on 2)

The method of claim 2, wherein the effector comprises a catheter.

### Claim 4

(canceled)

### Claim 5 (depends on 2)

The method of claim 2, wherein the effector comprises an ultrasound transducer adapted to deliver ultrasound energy through the wall of the renal pelvis.

### Claim 6 (depends on 5)

The method of claim 5, wherein the ultrasound transducer comprises a high intensity focused ultrasound transducer.

### Claim 7 (depends on 2)

The method of claim 2, wherein the effector comprises a deployable needle to deliver agents to the wall of the renal pelvis, the method further comprising piercing the wall of the renal pelvis with the needle to deliver an agent to effect nerve deactivation.

### Claim 8 (depends on 7)

The method of claim 7, wherein the agent is ethanol.

### Claim 9 (depends on 3)

The method of claim 3, wherein the effector comprises an iontophoresis catheter, the method further comprising applying an electric potential and injecting a nerve effecting agent.

### Claim 10 (depends on 2)

The method of claim 2, wherein the plurality of discrete lesions extend into the renal pelvic wall through a depth of 0.5 mm to 1.2 mm.

### Claim 11 (depends on 2)

The method of claim 2, further comprising at least partially evacuating the renal pelvis to at least partially collapse the walls of the renal pelvis.

### Claim 12 (depends on 2)

The method of claim 2, further comprising expanding the effector within the kidney or the upper region of the adjacent ureter to engage an interior wall of a renal pelvis such that the renal pelvic wall tissue of the renal pelvis is in contact with a portion of the distal end of the effector.

### Claim 13

A method for treating hypertension in a patient, the method comprising:
inserting a sheath through a ureter of the patient into a renal pelvis of the patient such that a distal end of the sheath is positioned within the renal pelvis or within a transition region where the ureter expands to meet the renal pelvis;
inserting an effector through the sheath and through the ureter of the patient into the renal pelvis of the patient such that a distal end of the effector is positioned within the renal pelvis or within a transition region where the ureter expands to meet the renal pelvis;
advancing the effector from the sheath into the renal pelvis; and
actuating the effector to contemporaneously create a plurality of discrete lesions in the renal pelvic tissue to disrupt the function of nerves contained in the renal pelvic wall;
wherein the effector is a catheter, an ultrasound transducer, or a deployable needle; and
wherein blood pressure of the patient is reduced.

### Claim 14 (depends on 13)

The method of claim 13, wherein the effector comprises a catheter.

### Claim 15

(canceled)

### Claim 16 (depends on 13)

The method of claim 13, wherein the effector comprises an ultrasound transducer adapted to deliver ultrasound energy through the wall of the renal pelvis.

### Claim 17 (depends on 16)

The method of claim 16, wherein the ultrasound transducer comprises a high intensity focused ultrasound transducer.

### Claim 18 (depends on 14)

The method of claim 14, wherein the effector comprises an iontophoresis catheter, the method further comprising applying an electric potential and injecting a nerve effecting agent.

### Claim 19 (depends on 13)

The method of claim 13, wherein the plurality of discrete lesions extend into the renal pelvic wall through a depth of 0.5 mm to 1.2 mm.

### Claim 20 (depends on 13)

The method of claim 13, further comprising at least partially evacuating the renal pelvis to at least partially collapse the walls of the renal pelvis.

### Claim 21 (depends on 13)

The method of claim 13, further comprising expanding the effector within the kidney or the upper region of the adjacent ureter to engage an interior wall of a renal pelvis such that the renal pelvic wall tissue of the renal pelvis is in contact with a portion of the distal end of the effector.
